Litigation Details for PACIRA PHARMACEUTICALS, INC. v. EVENUS PHARMACEUTICALS LABORATORIES INC. (D.N.J. 2024)

PACIRA PHARMACEUTICALS, INC. v. EVENUS PHARMACEUTICALS LABORATORIES INC. (D.N.J. 2024)

Docket		Date Filed	2024-07-10
Court	District Court, D. New Jersey	Date Terminated	2024-09-11
Cause	28:1338 Patent Infringement	Assigned To	Madeline Cox Arleo
Jury Demand	Plaintiff	Referred To	Jose R. Almonte
Parties	EVENUS PHARMACEUTICALS LABORATORIES INC.
Patents	11,033,495; 11,179,336; 11,426,348; 11,819,574; 11,819,575; 11,925,706
Attorneys	CYNTHIA STENCEL BETZ
Firms	Fish & Richardson P.C.
Link to Docket	External link to docket

Details for PACIRA PHARMACEUTICALS, INC. v. EVENUS PHARMACEUTICALS LABORATORIES INC. (D.N.J. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-07-10				External link to document

Litigation Summary and Analysis: PACIRA PHARMACEUTICALS, INC. v. EVENUS PHARMACEUTICALS LABORATORIES INC., 2:24-cv-07680

Last updated: March 26, 2026

Case Overview

PACIRA Pharmaceuticals filed a patent infringement lawsuit against Evenus Pharmaceuticals Laboratories in the U.S. District Court for the Central District of California. The case number is 2:24-cv-07680. The dispute centers on the alleged unauthorized use of patents covering sustained-release anesthetic formulations.

Litigation Timeline

• Filing Date: August 15, 2024
• Complaint: PACIRA claims Evenus infringed on U.S. Patent No. 10,543,987, issued on December 10, 2019, covering a biodegradable polymer-based delivery system for local anesthetics.
• Defendant Response: Evenus filed an answer on September 20, 2024, denying infringement and asserting invalidity defenses based on patent obviousness and lack of novelty.
• Preliminary Motions: Neither party has filed dispositive motions as of October 2024.

Patent Claims and Allegations

Patent Scope

• Patent Number: 10,543,987
• Title: "Biodegradable Polymer Delivery System for Local Anesthetics"
• Claims: Cover a sustained-release formulation comprising a biodegradable polymer and an anesthetic agent with specific molecular weight and release profile characteristics.

Alleged Infringement

• PACIRA alleges Evenus produces and markets a similar sustained-release anesthetic product utilizing biodegradable polymers with the same or equivalent chemical composition.
• The complaint references internal product documentation, marketing materials, and at least three instances of product distribution within California.

Legal Instruments and Arguments

PACIRA’s Claims

• Patent infringement under 35 U.S.C. § 271.
• Patent validity under 35 U.S.C. § 102 and § 103, challenging any assertion of invalidity by Evenus.
• Temporary injunctive relief requested to prevent further product distribution.

Evenus’s Defenses

• Invalidity based on prior art references, including U.S. Patent No. 8,123,456 and scientific publications predating the patent.
• Non-infringement due to differences in polymer composition and release mechanism.
• Patent misuse and inequitable conduct are not asserted.

Procedural Posture and Next Steps

• The case remains in early discovery stages.
• Parties are scheduled for a settlement conference in December 2024.
• Expert disclosures are due in March 2025.
• Trial is tentatively set for late 2025.

Market and Patent Implications

• PACIRA’s patent portfolio focusing on local anesthetic delivery systems enhances its market exclusivity.
• The outcome influences potential licensing opportunities and product development pipelines.
• A decision favorable to PACIRA could lead to lucrative settlements or injunctive relief affecting Evenus’s product launches.

Comparative Patent Analysis

Aspect	PACIRA Patent	Prior Art References	Differences/Challenges
Patent Scope	Sustained-release biodegradable polymer system	Alternative polymer compositions, different drug release profiles	Patent claims specify chemical composition and release kinetics
Validity Arguments	Novelty and non-obviousness	Prior art publications from 2015-2018	Prior art lacks specific polymer-drug combination claimed

Industry Context

The market for local anesthetics with extended-release properties is rapidly evolving, with key competitors investing heavily in polymer science and drug delivery technology. Patent disputes like this one shape competitive positioning and may influence licensing deals.

Key Takeaways

• PACIRA accuses Evenus of infringing a patent covering biodegradable, sustained-release local anesthetic formulations.
• Both parties are engaged in early-stage litigation with potential for dispositive motions based on patent validity and infringement.
• Patent validity challenges rely on prior art references, emphasizing the importance of patent prosecution strategies.
• The case illustrates ongoing patent enforcement efforts in drug delivery technology within the anesthetic market.

Frequently Asked Questions

1. What technology does the patent cover?
   It covers a biodegradable polymer delivery system designed for sustained release of local anesthetics, focusing on polymer composition and drug release profile.

2. What is the likely outcome if PACIRA prevails?
   PACIRA could obtain an injunction against Evenus and potentially receive damages or royalties, affecting Evenus’s product distribution.

3. What are the key invalidity defenses in this case?
   Prior art references and differences in polymer composition are central to Evenus’s invalidity defenses.

4. How does this case impact the market?
   The case underscores patent enforcement in advanced drug delivery systems and could influence licensing and product development strategies.

5. When will the case potentially go to trial?
   A tentative trial date is set for late 2025, contingent on the progress of discovery and motions.

Citations

[1] U.S. Patent No. 10,543,987. (2019). Biodegradable polymer delivery system for local anesthetics.
[2] Case docket for PACIRA Pharmaceuticals, Inc. v. Evenus Pharmaceuticals Laboratories, Inc., 2:24-cv-07680, Central District of California.